Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Recommendation of “Buy” from Brokerages

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been assigned an average rating of “Buy” from the five brokerages that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $19.80.

A number of analysts have recently commented on the company. StockNews.com upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research report on Wednesday. Finally, Piper Sandler cut their price objective on Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating for the company in a research report on Thursday, February 1st.

Aptose Biosciences Price Performance

Aptose Biosciences stock opened at $1.66 on Friday. The stock has a market capitalization of $26.10 million, a PE ratio of -0.22 and a beta of 1.30. Aptose Biosciences has a 12 month low of $1.36 and a 12 month high of $9.90. The business has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $2.34.

Institutional Trading of Aptose Biosciences

Several large investors have recently made changes to their positions in the company. DRW Securities LLC purchased a new stake in shares of Aptose Biosciences during the fourth quarter worth approximately $5,158,000. Renaissance Technologies LLC increased its position in shares of Aptose Biosciences by 3.6% during the first quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock worth $1,328,000 after purchasing an additional 33,952 shares in the last quarter. Annandale Capital LLC boosted its stake in Aptose Biosciences by 12.7% during the fourth quarter. Annandale Capital LLC now owns 800,000 shares of the biotechnology company’s stock worth $464,000 after buying an additional 90,000 shares during the last quarter. Millennium Management LLC boosted its stake in Aptose Biosciences by 75.4% during the fourth quarter. Millennium Management LLC now owns 222,930 shares of the biotechnology company’s stock worth $129,000 after buying an additional 95,796 shares during the last quarter. Finally, Sigma Planning Corp acquired a new position in Aptose Biosciences during the third quarter worth $408,000. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.